

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The invention listed below is owned by an agency of the U.S. Government and is available for licensing in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESSES: Invention Development and Marketing Unit, Technology Transfer Center, National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702, Rockville, MD 20850-9702.

FOR FURTHER INFORMATION CONTACT: Information on licensing, and copies of the U.S. patent applications listed below may be obtained by contacting: Attn. Invention Development and Marketing Unit, Technology Transfer Center, National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702, Rockville, MD 20850-9702, Tel. 240-276-5515 or email ncitechtransfer@mail.nih.gov. A signed Confidential Disclosure Agreement may be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.

Title of Invention: Improved Fixative for Paraffin-Embedded Tissue Samples.

Description of Technology

Tissues samples collected during medical procedures, such as biopsies, are used to diagnose a wide variety of diseases. Before diagnosis, patient samples are typically processed by fixation and paraffin embedding. This fixation/embedding process is used to preserve tissue morphology and histology for subsequent evaluation. Unfortunately, most fixative agents damage or destroy nucleic acids (RNA and DNA) and proteins, thereby potentially impairing diagnostic assessment of tissue.

Researchers in the National Cancer Institute's Laboratory of Pathology have developed an improved tissue fixative solution that is formaldehyde-free. This fixative, BE70, significantly improves DNA, RNA, and protein biomolecule integrity in histological samples

compared to traditional fixatives. Additionally, BE70 is compatible with current protocols and does not alter tissue processing. *In vitro an in vivo* data are available and the fixative has been tested on paraffin-embedded samples.

Potential Commercial Applications

- Improves integrity of fixed tissue samples.
- Improves RNA/DNA quality in fixed tissue samples.
- Non-cross linking, improves protein quality.

Value Proposition

- There is substantial interest in new fixatives to replace neutral buffered formalin (a carcinogen) as primary fixative agent for surgical pathology.
- BE70 overcomes several limitations of other fixatives, including cost and disposal issues.
- Could be formulated as a concentrate, and marketed as an additive (to be added during dilution of ethanol).

Development Stage

In vivo data: YES.

Inventor(s)

Stephen M. Hewitt (NCI), Joon-Yong Chung (NCI), Candice D. Perry (Leidos Biomedical LLC).

Intellectual Property

HHS Reference No. E-139-2015/0-US-01 US Provisional Patent Application 62/255,030 (HHS Reference No. E-139-2015/0-US-01) filed November 13, 2015, entitled "Fixative and Methods of Use".

Publications

Perry C, Chung JY, et al. *J Histochem Cytochem*. 2016 May 24; E-pub [PMID: 27221702].

Contact Information

Requests for copies of the patent application or inquiries about licensing, research collaborations, and co-development opportunities should be sent to John D. Hewes, Ph.D., email: john.hewes@nih.gov.

Dated: June 28, 2016.

John D. Hewes,

Technology Transfer Specialist, Technology Transfer Center, National Cancer Institute.

[FR Doc. 2016-15890 Filed 7-5-16; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Aging; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Aging Special Emphasis Panel; Delirium Research Networks.

Date: July 29, 2016.

Time: 2:00 p.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institute on Aging, Gateway Building, Suite 2W200, 7201 Wisconsin Avenue, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Isis S. Mikhail, DRPH, MD, MPH, National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Suite 2W200, Bethesda, MD 20892, 301-402-7704. mikhaili@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS)

Dated: June 29, 2016.

Melanie J. Gray,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2016-15882 Filed 7-5-16; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial